Israel Pharmaceuticals and Healthcare Market Report Q1 2012

2011-12-28
Published : Dec-2011

BMI View: Our opinion that industrial action in Israel would result in an increase in public healthcare expenditure has played out. The government is promising an additional ILS2.7bn (US$764mn) a year for doctors’ salaries and public health in general. This is a significantly larger increase than we had forecast (US$106mn) and we have adjusted our forecasts accordingly. Some doctors have resisted the new agreement, saying it does not go far enough, but BMI does not expect the government to make any significant further concessions.

Israel Pharmaceuticals and Healthcare Market Report Q1 2012

Order Now, Contact: + 1 888 391 5441 or [email protected]

Headline Expenditure Projections

Pharmaceuticals: ILS6.72bn (US$1.80bn) in 2010 to ILS6.98bn (US$1.98bn) in 2011; +3.9% in local currency terms and +10.0% in US dollar terms. This is down in US dollar terms from Q411 due to a downward revision to macroeconomic figures.

Healthcare: ILS59.77bn (US$16.01bn) in 2010 to ILS62.42bn (US$18.31bn) in 2011; +4.4% in local currency terms and +10.5% in US dollar terms. This is up from Q411 in local currency terms, due to government concessions to medical staff. However, in US dollar terms the forecast is down because of a downward revision to macroeconomic figures.

Medical devices: ILS3.66bn (US$980mn) in 2010 to ILS3.81bn (US$1.08bn) in 2011; +4.2% in local currency terms and +10.2% in US dollar terms. This is down in US dollar terms from Q411 due to a downward revision to macroeconomic figures.

Business Environment Rating: In our latest regional BERs, Israel ranks fifth, out of the 30 markets surveyed in MEA. This is down from third in Q411 due to a downgrade to the country’s currency forecast for 2011-2013. This consequence of this reduction is a slowing in the market’s growth in US dollar terms, which is a key component of the country reward score.

Key Trends And Developments:

In an effort to control an increasingly hostile domestic political situation, the government signed a new pay deal with the country’s doctors that includes an average pay increase of 49% on their hourly wage, a promise to hire and train 1,000 more doctors to alleviate shortages, and incentives for doctors who work outside of the main population centres and in specialist medical areas with staff shortages. The changes to the terms of their contracts are to be applied retroactively to July 2010 and remain in place until 2019, so the doctors can probably expect a cash windfall that will also increase public healthcare expenditure in 2011.

Israel is in the process of aligning its good manufacturing practice (GMP) and good distribution practice (GDP) legislation with EU directives 2003/94/EC and 2001/83/EC. The result of these changes will be an increasing onus on pharmaceutical importers to assure the quality of their products and their supply chains. This will be partnered with an increase in system oversight, including an authorisation process for importers and the introduction of a three-year maximum jail term for people that break the new rules.

BMI Economic View: The Bank of Israel (BoI)’s decision to cut its headline interest rate from 3.25% to 3.00% on September 26 2011 came in response to growing concern over global growth. Given declining inflation rates and expectations, we see potential for further rate cuts over the medium term and consequently we have revised down our 2012 headline rate forecast from 4.00% to 2.75%. BMI Political View: The announcement on September 15 2011 of the Israeli reform committee’s recommendations for dealing with public unrest will not appease protestors. Most of the measures are not enough to bring about the change that protestors demand and we anticipate a resurgence in large demonstrations.

The possibility of an Israeli air strike on Iran should not be underestimated. Rumours about potential Israeli military action have were reported in the media in November 2011 and while we still believe the costs of an air war would outweigh the benefits, Israeli decision makers may decide otherwise. We reiterate that a military confrontation between Israel and Iran would create a new global crisis, threatening to spiral into a regional war, which would in turn drive up oil prices.

Executive Summary
SWOT Analysis
Israel Pharmaceuticals And Healthcare Industry SWOT
Israel Political SWOT
Israel Economic SWOT
Israel Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Middle East And Africa Pharmaceutical And Healthcare Business Environment Ratings, Q112
Rewards
Risks
Israel – Market Summary
Regulatory Regime
Intellectual Property
IP Environment Shortcomings
Counterfeit Drugs
Pricing System
Table: Price Build-Up In The Israeli Pharmaceutical Market
Price Cuts
Reimbursement System
Reimbursement Developments
Reimbursement Funding
Industry Trends and Developments
Epidemiology
Communicable Diseases
Healthcare Sector
Healthcare Insurance
Recent Healthcare Coverage Developments
Healthcare Financing
Research And Development Sector
Table: Israel’s R&D Law – Conditions For OCS Funding
Clinical Trials
Biotechnology
Biotechnology Developments
Private Sector Research And Development
Medical Device Industry
Medical Device Company Developments
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales, 2007-2016
Key Growth Factors – Industry
Table: Healthcare Expenditure, 2007-2016
Key Growth Factors – Macroeconomic
Table: Israel Economic Activity, 2006-2015
Prescription Market Forecast
Table: Prescription Drug Sales, 2007-2016
Patented Drug Market Forecast
Table: Patented Drug Sales, 2007-2016
Generic Drug Market Forecast
Table: Generic Drug Sales, 2007-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales, 2007-2016
Medical Device Market Forecast
Table: Medical Device Sales, 2007-2016
Pharmaceutical Trade Forecast
Table: Pharmaceuticals Trade, 2007-2016
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Domestic Pharmaceutical Industry
Table: Selection Of Teva’s Acquisitions
Foreign Pharmaceutical Industry
Recent Pharmaceutical Company Developments
Company Profiles
Domestic Manufacturers
Teva Pharmaceutical Industries
Taro
Perrigo (Agis Industries)
Dexcel
Neopharm Group
Trima
Rekah
Multinational Companies
Pfizer
GlaxoSmithKline
Novartis
Sanofi
Merck & Co
Country Snapshot: Israel Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
$4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
$

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
$4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
$4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
$4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
$4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
$4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
$4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
$4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
$4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy